Modern methods for diagnosis and therapy of cutaneous T-cell lymphoma


如何引用文章

全文:

详细

Cutaneous T-cell lymphomas (T-CCL) are a clinically and morphologically heterogeneous group of cutaneous malignant tumors, caused by monoclonal proliferation of lymphoid tissue cells in the skin. They are responsible for about 80% of all primary cutaneous lymphomas, while cutaneous lymphomas are responsible for 2% of all dermatological diseases. The incidence of T-CCL is now increasing all over the world: 3% annual increment only in the USA and EEC countries and up to 800 new cases annually in the Russian Federation. The disease diagnosis is difficult because it imitates other chronic dermatoses. For this reason, effective methods for diagnosis verification are developed. Modern armory of methods for T-CCL treatment allows individual choice of therapy with consideration for disease stage.

作者简介

O. Olisova

I.M. Setchenov First Moscow State Medical University

Email: olisovaolga@mail.ru
Кафедра кожных и венерических болезней им. В.А. Рахманова лечебного факультета; доктор мед. наук, профессор 119991, Moscow, Russia

E. Anpilogova

I.M. Setchenov First Moscow State Medical University

Email: truelass@hotmail.com
student 119991, Moscow, Russia

参考

  1. Анпилогова Е.М. Т-клеточные лимфомы кожи: этиопатогенез, классификация, клиника. Российский журнал кожных и венерических болезней. 2015; 3: 42-7.
  2. Молочков А.В., Ковригина А.М., Кильдюшевский А.В., Караулов А.В. Лимфома кожи. М.: БИНОМ; 2012.
  3. Куклин И.А. Диагностика и лечение больных эритродермическими формами злокачественной Т-клеточной лимфомы кожи: Автореф. дис. … канд. мед. наук. Екатеринбург; 2005.
  4. Овсянникова Г.В. Современные методы комплексной диагностики злокачественных лимфом кожи: Автореф. дис. … канд. мед. наук. М.; 2009.
  5. Лезвинская Е.М., Вавилов А.М. Лимфопролиферативные опухоли кожи. Руководство для врачей. М.: Практическая медицина; 2010: 87-105.
  6. Тарасов В.В. Терапия лимфом кожи (отдаленные результаты и прогноз): Автореф. дис. … канд. мед. наук. СПб.; 2011.
  7. Jaffe E.S., Harris N.L., Vardiman J.W., Campo E., Arber D.A. Hematopathology. Saunders Elsevier; 2011: 36-45.
  8. Bolognia J.L., Jorizzo J.L., Schaffer J. Dermatology. Elsevier Science; 2012.
  9. McPherson R.A., Pincus M.R. Henry’s clinical diagnosis and management by laboratory methods. Saunders Elsevier; 2011: 1271-81.
  10. Федоровская А.В. Совершенствование методов дифференциальной диагностики эритродермической формы Т-клеточной лимфомы кожи: Автореф. дис. … канд. мед. наук. М.; 2012.
  11. Clark D.P., Pazdernik N.J. Molecular Biology. Elsevier; 2013: 55-61.
  12. Niederhuber J.E., Armitage J.O., Doroshow J.H., Kastan M.B., Tepper J.E. Abeloff’s clinical oncology. Elsevier; 2014: 2060-75.
  13. Calonje E., Brenn T., Lazar A., McKee P.H. McKee’s pathology of the skin: with clinical correlations. Saunders Elsevier; 2012: 1311-420.
  14. Ferri F. Ferri’s clinical advisor 2016. Elsevier; 2015: 838-9.
  15. Adkinson F.N., Bochner B.S., Burks W.A., Busse W.W., Holgate S.T., Lemanske R.F., O’Hehir R.E. Middleton’s allergy: principles and practice. Saunders Elsevier; 2014: 1587-92.
  16. Formal L. Mycosis fungoides treated with prednisone. Proc. R. Soc. Med. 1957; 50(11): 936.
  17. Кохан М.М. Т-клеточные злокачественные лимфомы кожи: клинические и иммунологические аспекты диагностики, стадийного лечения и терапии: Автореф. дис. … д-ра мед. наук. Екатеринбург; 2002.
  18. Фараджев З.Г. Лимфопролиферативные заболевания кожи и саркома Капоши: Автореф. дис. ... д-ра мед.наук. М.; 1990.
  19. Аравийская Е.Р. Клинико-морфологическая характеристика пойкилодермической формы лимфомы кожи: особенности течения, диагностики и терапии проспидином: Автореф. дис. … канд. мед. наук. СПб.; 1993.
  20. Zackheim H.S., Kashani-Sabet M., Hwang S.T. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J. Am. Acad. Dermatol. 1996; 34(4): 626-31.
  21. Bunn P.A., Hoffman S.J., Norris D., Golitz L.E., Aeling J.L. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sйzary syndrome). Ann. Intern. Med. 1994; 121(8): 592-602.
  22. Akpek G., Koh H.K., Bogen S., O’Hara C., Foss F.M. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999; 86(7): 1368-76.
  23. Kaye F.J., Bunn P.A., Steinberg S.M., Stocker J.L., Ihde D.C., Fischmann A.B., et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N. Engl. J. Med. 1989; 321(26): 1784-90.
  24. Mendelsohn J., Gray J.W., Howley P.M., Israel M.A., Thompson C.B. Molecular basis of cancer. Saunders Elsevier; 2015: 739-52.
  25. Saiki I., Dunegan M.A., Fann A.V., Koff W.C. Regulatory effects on macrophages of human recombinant interferons-alpha. J. Interferon Res. 1986; 6(5): 603-11.
  26. Lebwohl M.G., Heymann W.R., Berth-Jones J., Coulson I. Treatment of skin disease: comprehensive therapeutic strategies. Elsevier Limited; 2014: 430-4.
  27. Fung M.A., Murphy M.J., Hoss D.M., Grant-Kels J.M. Practical Evaluation and management of cutaneous lymphoma. J. Am. Acad. Dermatol. 2002; 46(3): 325-60.
  28. Izu-Belloso R.M., Garcia-Ruiz J.C. Treatment of cutaneous lymphomas: an update. Actas Dermo-Sifiliogr. 2012; 103(8): 694-707.
  29. Rajan G.P., Seifert B., Prьmmer O., Joller-Jemelka H.I., Burg G., Dummer R. Incidence and in vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Arch. Dermatol. Res. 1996; 288(9): 543-8.
  30. Dao H.Jr., Barr P.M., Honda K. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox. J. Am. Acad. Dermatol. 2011; 64(6): e123-5. doi: 10.1016/j.jaad.2010.11.001.
  31. Виноградова Ю.Е., Потекаев Н.С., Виноградов Д.Л. Лимфомы кожи: диагностика и лечение. М.: Практическая медицина; 2014.
  32. Lundin J., Kimby E., Bjцrkholm M., Broliden P.A., Celsing F., Hjalmar V., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab. (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002; 100(3): 768-73.
  33. Kennedy G.A., Seymour J.F., Wolf M., Januszewicz H., Davison J., McCormack C., et al. Treatments of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur. J. Haematol. 2003; 71(4): 250-6.
  34. Abbott R.A., Whittaker S.J., Morris S.L., Russell-Jones R., Hung T., Bashir S.J., Scarisbrick J.J. Bexarotene therapy for mycosis fungoides and Sйzary syndrome. Br. J. Dermatol. 2009; 160(6): 1299-307.
  35. Dicken C.H., Connolly S.M. Systemic retinoids in dermatology. Mayo Clin. Proc. 1982; 57(1): 51-7.
  36. Cheeley J., Sahn R.E., DeLong L.K., Parker S.R. Acitretin for the treatment of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 2012; 68(2): 247-54. doi: 10.1016/j.jaad.2012.07.013.
  37. Firestein G.S., Budd R.C., Gabriel Sh.E., McInnes I.B., O’Dell J.R. Kelley’s textbook of rheumatology. Saunders Elsevier; 2013: 941-56.
  38. Tugwell P., Ludwin D., Gent M., Roberts R., Bensen W., Grace E., Baker P. Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J. Rheumatol. 1997; 24(6): 1122-5.
  39. Campana C., Regazzi M.B., Buggia I., Molinaro M. Clinically significant drug interactions with cyclosporine: an update. Clin. Pharmacokinet. 1996; 30(2): 141-79.
  40. Cooper D.L., Braverman I.M., Sarris A.H., Durivage H.J., Saidman B.H., Davis C.A., Hait W.N. Cyclosporine treatment of refractory T-cell lymphomas. Cancer. 1993; 71(7): 2335-41.
  41. Maddox A.M., Kahan B.D., Tucker S., Kerman R., Jordan R.E. Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporine. J. Am. Acad. Dermatol. 1985; 12(5): 952-6.
  42. Hoffmann R., Benz E.J., Silberstein L.E., Heslop H.E., Weitz J.I., Anastasi J. Hematology: Basic principles and practice. Saunders Elsevier; 2013: 1267-302.
  43. Wolverton S.E. Comprehensive dermatologic drug therapy. Saunders Elsevier; 2013: 279-90.
  44. Олисова О.Ю. Достоинства и недостатки фототерапии. Экспериментальная и клиническая дерматокосметология. 2013; 2: 13-17.
  45. Gilchrest B.A., Parrish J.A., Tannenbaum L., Hayness H.A., Fitzpatrick T.B. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer. 1976; 38(2): 683-689.
  46. Hölzle E., Hönigsmann H. UV-radiation - sources, wavelength, environment. J. Dtsch. Dermatol. Ges. 2005; 3(Suppl. 2): S3-10.
  47. Hönigsmann H., Diepgen T.L. UV-induced skin cancers. J. Dtsch. Dermatol. Ges. 2005; 3(Suppl. 2): S26-31.
  48. Hönigsmann H. Mechanisms of phototherapy and photochemotherapy for photodermatoses. Dermatol. Ther. 2003; 16(1): 23-7.
  49. Herrmann J.J., Roenigk H.H., Hurria A., Kuzel T.M., Samuelson E., Rademaker A.W., Rosen S.T. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J. Am. Acad. Dermatol. 1995; 33(2): 234-42.
  50. Thomsen K., Hammar H., Molin L., Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis fungoides Group. Acta. Derm. Venereol. 1989; 69(6): 536-8.
  51. Hӧlzle E., Hӧnigsmann H., Rӧcken M., Ghoreschi K., Lehmann P. Recommendations for phototherapy and photochemotherapy. J. Dtsch. Dermatol. Ges. 2003; 1(12): 985-97.
  52. Herrmann J.J., Roenigk H.H.Jr., Hӧnigsmann H. Ultraviolet radiation for treatment of cutaneous T cell lymphoma. Hematol. Oncol. Clin. North. Am. 1995; 9(5): 1077-88.
  53. Hӧnigsmann H. Phototherapy and photochemotherapy. Semin. Dermatol. 1990; 9(1): 84-90.
  54. Hönigsmann H. Indications for UV-B irradiation. Hautarzt. 1993; 44(8): 545.
  55. Pirkhammer D., Seeber A., Hönigsmann H., Tanew A. Narrowband ultraviolet B (TL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br. J. Dermatol. 2000; 143(5): 964-8.
  56. Lee E., Koo J., Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int. J. Dermatol. 2005; 44(5): 355-60.
  57. Gerber W., Arheilger B., Ha T.A., Hermann J., Ockenfels H.M. Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach. Br. J. Dermatol. 2003; 149(6): 1250-8.
  58. Spencer J.M., Hadi S.M. The excimer lasers. J. Drugs Dermatol. 2004; 3(5): 522-5.
  59. Totonchy M.B., Chiu M.W. UV-based therapy. Dermatol. Clin. 2014; 32(3): 399-413.
  60. Mori M., Campolmi P., Mavilia L., Rossi R., Cappugi P., Pimpinelli N. Monochromatic excimer light (308 nm) in patch-stage IA mycosis fungoides. J. Am. Acad. Dermatol. 2004; 50(6): 943-45.
  61. Ratcliffe N., Dunbar N.M., Adamski J., Couriel D., Edelson R., Kitko C.L., et al.; American Society for Apheresis. National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. Transfus. Med. Rev. 2015; 29(1): 62-70. doi: 10.1016/j.tmrv.2014.09.004.
  62. Shaz B.H., Hillyer Ch.D., Roshal M., Abrams Ch.S. Transfusion medicine and hemostasis: clinical and laboratory aspects. Elsevier; 2013: 515-20.
  63. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus. Apher. Sci. 2003; 29(1): 61-70.
  64. Гостева И.В. Фотоферез в комплексной терапии Т-клеточных злокачественных лимфом кожи: Автореф. дис. … канд. мед. наук. М.; 1995.
  65. Гостева И.В. Применение фотофереза в лечении Т-клеточных злокачественных лимфом кожи. Российский журнал кожных и венерических болезней.1998; 3: 11-7.
  66. Wollina U., Looks A., Meyer J., Knopf B., Koch H.J., Liebold K., Hipler U.C. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J. Am. Acad. Dermatol. 2001; 44 (2): 253-60.
  67. Hoppe R.T., Cox R.S., Fuks Z., Price N.M., Bagshaw M.A., Farber E.M. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat. Rep. 1979; 63(4): 691-700.
  68. Jones G.W., Hoppe R.T., Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 1995; 9(5): 1057-76.
  69. Jones G.W., Kacinski B.M., Wilson L.D., Willemze R., Spittle M., Hohenberg G., et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J. Am. Acad. Dermatol. 2002; 47(3): 364-70.
  70. Jones G.W., Rosenthal D., Wilson L.D. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer. 1999; 85(9): 1985-95.
  71. Yu J.B., McNiff J.M., Lund M.W., Wilson L.D. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70(5): 1542-5.
  72. Maingon P., Truc G., Dalac S., Barillot I., Lambert D., Petrella T., et al. Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation. Radiother. Oncol. 2000; 54(1): 73-8.
  73. Gunderson L., Tepper J. Clinical radiation oncology. Saunders Elsevier; 2012: 1583-603.

版权所有 © Eco-Vector, 2015


 


##common.cookie##